General MedicationsINJECTIONStandard
PAVBLU
AFLIBERCEPT-AYYH
Standard Dose
2 mg (0.05 mL of 40 mg/mL)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview PAVBLU is listed in Drugs@FDA under application 761298 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient AFLIBERCEPT-AYYH Form and strength INJECTABLE;INJECTION - 2 mg (0.05 mL of 40 mg/mL) Sponsor AMGEN INC Submission history Latest submission status date: 2024-08-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview PAVBLU is listed in Drugs@FDA under application 761298 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient AFLIBERCEPT-AYYH Form and strength INJECTABLE;INJECTION - 2 mg (0.05 mL of 40 mg/mL) Sponsor AMGEN INC Submission history Latest submission status date: 2024-08-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.